0000950123-20-006737.txt : 20200706
0000950123-20-006737.hdr.sgml : 20200706
20200706210132
ACCESSION NUMBER: 0000950123-20-006737
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200701
FILED AS OF DATE: 20200706
DATE AS OF CHANGE: 20200706
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Brown Bob D
CENTRAL INDEX KEY: 0001598479
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36281
FILM NUMBER: 201015043
MAIL ADDRESS:
STREET 1: 87 CAMBRIDGEPARK DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
FORMER NAME:
FORMER CONFORMED NAME: Brown Bob
DATE OF NAME CHANGE: 20140129
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Dicerna Pharmaceuticals Inc
CENTRAL INDEX KEY: 0001399529
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 205993609
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 33 HAYDEN AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 617 621 8097
MAIL ADDRESS:
STREET 1: 33 HAYDEN AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
4
1
doc4.xml
PRIMARY DOCUMENT
X0306
4
2020-07-01
0
0001399529
Dicerna Pharmaceuticals Inc
DRNA
0001598479
Brown Bob D
C/O DICERNA PHARMACEUTICALS, INC.
33 HAYDEN AVENUE
LEXINGTON
MA
02421
0
1
0
0
See Remarks
Common Stock
2020-07-01
4
M
0
8185
3.42
A
13185
D
Common Stock
2020-07-01
4
S
0
5814
26.3604
D
7371
D
Common Stock
2020-07-01
4
S
0
2371
26.8533
D
5000
D
Employee Stock Option (Right to Buy)
3.42
2020-07-01
4
M
0
8185
0.00
D
2023-09-24
Common Stock
8185
40925
D
The Reporting Person sold an aggregate of 8,185 shares of common stock on July 1, 2020 (the "Shares Sold") as reported in this Form 4. The Shares Sold represent 0.83% of 981,327 shares of common stock, which is the number of shares of common stock owned by the Reporting Person prior to the Shares Sold transaction reported in this Form 4, as well as shares issuable upon exercise or settlement of vested and unvested options and restricted stock units held by the Reporting Person as of the date of this report.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2019.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.70 to $26.68, inclusive. The Reporting Person undertakes to provide to Dicerna Pharmaceuticals, Inc., any security holder of Dicerna Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.73 to $26.97, inclusive. The Reporting Person undertakes to provide to Dicerna Pharmaceuticals, Inc., any security holder of Dicerna Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.
The vesting of these options was subject to achievement of pre-established performance goals. As of the transaction date, the options were fully vested.
Chief Scientific Officer, EVP of R&D
/s/ Douglas W. Pagan, attorney-in-fact
2020-07-06